Abstract 2482: Effect of Intracoronary Anisodamine on No-Reflow Phenomenon after PCI in Mini-Pig with AMI
Background Since 1970s, Anisodamine has been proved ,by many basic and clinic studies,that had the spescial effects on releasing microvessel spasm, improving and dredging the microcirculation, inhibiting platelete aggregation, decreasing blood viscosity, and increasing the tolerance of myocardium to ischemia. As an inhibitor of M-cholinergic receptor, Anisodamine plays strong effectiveness, releasing the coronary microvessle spasm, so that it may be beneficial for the improvement of no- reflow phenomenon following PCI for AMI, so we first evaluate the effect of intracoronary anisodamine to correct the no-reflow phenomenon during AMI in no-reflow minipig model made by superselective LAD with 4F catheter then injection of micro thrombus.
Method: Fourteen no-reflow minipig models were randomized into intracoronary saline (4ml), diltiazem (1mg diluted to 4ml) and anisodamine (2mg to 4 ml) groups. CAG was performed at 1, 3, 5, 10th minute after intracoronary injection. Corrected TIMI frame count and coronary artery diameter were obtained by QCA, meanwhile ECG and hemodynamic parameters (HR, LVEDP, intracoronary MAP,) were recorded.
Results The corrected TIMI frame count in Anisodamine group was significantly decreased by 13.2%, 25.3%, 35.6%, 33.6% at 1, 3, 5, 10 th minute compared with saline group, while decreased by 10.6%, 20.4%, 14.3%, 21.5% at 1, 3, 5, 10 th minute compared with diltiazem group(, respectively). The medial LAD diameter in Anisodamine group increased from 2.12±0.38mm to 2.60±0.43mm (P<0.05) while to 2.51±0.42mm in diltiazem group as compared before(P<0.05). HR and intracoronary MAP were increased and LVEDP reduced at 1, 3, 5, 10 th minute after administration of anisodamine, which had significance compared with group NS (125±20 vs 140±25bpm, 95±12 vs 126±13mmHg,P<0.05), accompanied with HR increasing (P<0.05). It was very important that No serious side effect and toxic reaction were found.
Conclusions: The injection of intracoronary anisodamine might produce coronary microcirculative and hemodynamic improvement, with reversing the no-reflow phenomenon after PCI-AMI in mini-pig.